Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 6.95
NVIV's Cash to Debt is ranked higher than
75% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. NVIV: 6.95 )
NVIV' s 10-Year Cash to Debt Range
Min: 6.94   Max: No Debt
Current: 6.95

F-Score: 3
Z-Score: 9.76
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -165.48
NVIV's ROE (%) is ranked lower than
55% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. NVIV: -165.48 )
NVIV' s 10-Year ROE (%) Range
Min: -775.86   Max: -195.09
Current: -165.48

-775.86
-195.09
ROA (%) -101.04
NVIV's ROA (%) is ranked lower than
55% of the 513 Companies
in the Global Medical Devices industry.

( Industry Median: 0.75 vs. NVIV: -101.04 )
NVIV' s 10-Year ROA (%) Range
Min: -1218.1   Max: 42.86
Current: -101.04

-1218.1
42.86
ROC (Joel Greenblatt) (%) -901.51
NVIV's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 5.44 vs. NVIV: -901.51 )
NVIV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3330.38   Max: -817.6
Current: -901.51

-3330.38
-817.6
EBITDA Growth (3Y)(%) -33.30
NVIV's EBITDA Growth (3Y)(%) is ranked higher than
54% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 1.50 vs. NVIV: -33.30 )
NVIV' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -62.2   Max: 543.1
Current: -33.3

-62.2
543.1
EPS Growth (3Y)(%) -32.30
NVIV's EPS Growth (3Y)(%) is ranked higher than
57% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. NVIV: -32.30 )
NVIV' s 10-Year EPS Growth (3Y)(%) Range
Min: -62.2   Max: 544.7
Current: -32.3

-62.2
544.7
» NVIV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NVIV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 65.52
NVIV's P/B is ranked lower than
64% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. NVIV: 65.52 )
NVIV' s 10-Year P/B Range
Min: 0   Max: 67.4
Current: 65.52

0
67.4
EV-to-EBIT -22.93
NVIV's EV-to-EBIT is ranked higher than
54% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NVIV: -22.93 )
NVIV' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -22.93

Current Ratio 1.63
NVIV's Current Ratio is ranked higher than
54% of the 502 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. NVIV: 1.63 )
NVIV' s 10-Year Current Ratio Range
Min: 0.14   Max: 6.67
Current: 1.63

0.14
6.67
Quick Ratio 1.63
NVIV's Quick Ratio is ranked higher than
64% of the 502 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. NVIV: 1.63 )
NVIV' s 10-Year Quick Ratio Range
Min: 0.14   Max: 6.67
Current: 1.63

0.14
6.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 148.91
NVIV's Price/Net Cash is ranked higher than
74% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NVIV: 148.91 )
NVIV' s 10-Year Price/Net Cash Range
Min: 18.37   Max: 48
Current: 148.91

18.37
48
Price/Net Current Asset Value 90.99
NVIV's Price/Net Current Asset Value is ranked higher than
63% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. NVIV: 90.99 )
NVIV' s 10-Year Price/Net Current Asset Value Range
Min: 17.33   Max: 29.33
Current: 90.99

17.33
29.33
Price/Tangible Book 65.52
NVIV's Price/Tangible Book is ranked lower than
61% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 8.30 vs. NVIV: 65.52 )
NVIV' s 10-Year Price/Tangible Book Range
Min: 3.96   Max: 19.38
Current: 65.52

3.96
19.38
Earnings Yield (Greenblatt) -4.40
NVIV's Earnings Yield (Greenblatt) is ranked higher than
56% of the 493 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. NVIV: -4.40 )
NVIV' s 10-Year Earnings Yield (Greenblatt) Range
Min: -29.4   Max: 1000
Current: -4.4

-29.4
1000

Business Description

Industry: Medical Devices » Medical Devices
Compare: » details
InVivo Therapeutics Holdings Corp. was incorporated on April 2, 2003, under the name of Design Source, Inc. The Company develops novel biomaterial technologies for the treatment of spinal cord injuries and hydrogels for therapeutics delivery. It is also developing an injectable, resorbable family of hydrogels for localized, controlled release of small molecules and proteins. Under the CMCC License, the Company has the right to sublicense the patents and have full control and authority over the development and commercialization of the licensed products, including clinical trials, manufacturing, marketing, and regulatory filings. The Comany also own the rights to the data generated pursuant to the CMCC License. The Company competes with major drug companies, specialized biotechnology firms, academic institutions, government agencies and private and public research institutions. The Company is subject to evolving federal, state and local environmental, health and safety laws and regulations.
» More Articles for NVIV

Headlines

Articles On GuruFocus.com

More From Other Websites
Coverage initiated on InVivo Therapeutics by H.C. Wainwright Apr 17 2015
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) to Ring The Nasdaq Stock Market Opening Bell Apr 16 2015
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV) to Ring The Nasdaq Stock Market Opening Bell Apr 16 2015
InVivo Therapeutics Announces Uplisting to Nasdaq Apr 16 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Other Events, Financial Statements and... Apr 16 2015
8:01 am InVivo Therapeutics announces uplisting to The Nasdaq Capital Market; will trade under NVIV... Apr 16 2015
InVivo Therapeutics Announces Uplisting to Nasdaq Apr 16 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Other Events Apr 08 2015
InVivo Therapeutics Announces Implementation of Reverse Stock Split in Preparation for Planned... Apr 08 2015
InVivo Therapeutics Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Apr 01 2015
InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update Apr 01 2015
InVivo Therapeutics Exhibiting at 66th Southern Neurosurgical Society Annual Meeting Apr 01 2015
InVivo Therapeutics Announces Keck Hospital of University of Southern California as New Site for... Apr 01 2015
InVivo Therapeutics Announces New Clinical Trial Site for Neuro-Spinal Scaffold Apr 01 2015
InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for... Apr 01 2015
InVivo Therapeutics Announces University of Kansas Medical Center as New Site for Neuro-Spinal... Apr 01 2015
InVivo Therapeutics Announces New Clinical Trial Site for Neuro-Spinal Scaffold Apr 01 2015
InVivo Therapeutics Announces University of Kansas Medical Center as New Site for Neuro-Spinal... Mar 30 2015
InVivo Therapeutics Exhibiting at 66th Southern Neurosurgical Society Annual Meeting Mar 27 2015
InVivo Therapeutics Announces Reopening of Enrollment for Subjects Three through Five for... Mar 26 2015
InVivo Therapeutics Announces Keck Hospital of University of Southern California as New Site for... Mar 25 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Material Modification to Rights of Security... Mar 24 2015
InVivo Therapeutics Announces Reverse Stock Split in Preparation for Planned Uplisting to NASDAQ Mar 24 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Financials Mar 18 2015
InVivo Therapeutics Reports 2014 Year End Financial Results and Business Update Mar 11 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 10-K, Annual Report Mar 11 2015
InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial... Feb 23 2015
InVivo Therapeutics Announces Froedtert & the Medical College of Wisconsin as New Clinical Trial... Feb 23 2015
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer Feb 09 2015
InVivo Therapeutics Appoints Lorianne Masuoka, MD as Chief Medical Officer Feb 09 2015
InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board Feb 05 2015
InVivo Therapeutics Announces CEO Mark Perrin Named Chairman of the Board Feb 05 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K/A, Entry into a Material Definitive Agreement,... Jan 29 2015
INVIVO THERAPEUTICS HOLDINGS CORP. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Jan 29 2015
InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted... Jan 21 2015
InVivo Therapeutics Reports Three-Month Update of First Acute Spinal Cord Injury Subject Implanted... Jan 21 2015
InVivo Therapeutics Announces Reopening of Enrollment for Ongoing Pilot Trial Jan 09 2015
InVivo Therapeutics Announces FDA Approval to Expedite Enrollment for Ongoing Pilot Trial Dec 16 2014
InVivo Therapeutics Announces University of Pittsburgh Medical Center Presbyterian as New Clinical... Nov 25 2014
InVivo Therapeutics Announces Oregon Health & Science University as Fifth Clinical Trial Site for... Nov 21 2014
InVivo Therapeutics Announces Appointment of Ann Merrifield to Its Board of Directors Nov 11 2014
InVivo Therapeutics Reports 2014 Third Quarter Financial Results and Business Update Nov 05 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK